Related Experiment Video
Updated: Feb 8, 2026

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
Published on: December 19, 2017
Pharmacogenetic of voriconazole antifungal agent in pediatric patients
Sarah Allegra1, Giovanna Fatiguso1, Silvia De Francia2
1Department of Medical Sciences, University of Turin - ASL 'Città di Torino', Amedeo di Savoia Hospital, Corso Svizzera 164, 10149 Turin, Italy.
Aim:
We explored the role of SNPs within the SLCO1B3, SLCO1B1, SLC22A6, ABCB1, ABCG2, SLCO3A1, CYP2C19, ABCC2, SLC22A1, ABCB11 and NR1I2 genes on voriconazole pharmacokinetics.
Patients & Methods:
233 pediatric patients were enrolled. Drug plasma Ctrough was measured by a HPLC-MS method. Allelic discrimination was performed by qualitative real-time PCR.
Results:
SLCO1B3 rs4149117 c.334 GT/TT (p = 0.046), ABCG2 rs13120400 c.1194 + 928 CC (p = 0.029) and ABCC2 rs717620 c.-24 GA/AA (p = 0.025) genotype groups significantly influenced Ctrough. ethnicity (p = 0.042), sex (p = 0.033), SLCO1B3 rs4149117 c.334 GT/TT (p = 0.041) and ABCB1 rs1045642 c.3435 TT (p = 0.016) have been retained in linear regression model as voriconazole predictor factors.
Conclusion:
Understanding how some gene polymorphisms affect the voriconazole pharmacokinetic is essential to optimally dose this agent.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Subviral Agents
Air-entraining Agents

